VEGFA and pancreatic neuroendocrine tumor: Results of CALGB 80701, a phase II trial of patients with advanced pancreatic NETs randomized to receive either everolimus and octreotide or everolimus plus bevacizumab and octreotide, will provide additional information about the benefits of combined mTOR and VEGF pathway inhibition (clinical trials.gov, NCT01229943).